A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients With Non-small Cell Lung Cancer, With Expansion Cohorts in Patients With Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient Colorectal Cancer

Trial Profile

A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients With Non-small Cell Lung Cancer, With Expansion Cohorts in Patients With Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient Colorectal Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Nov 2017

At a glance

  • Drugs Entinostat (Primary) ; Pembrolizumab (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ENCORE 601; KEYNOTE 142
  • Sponsors Syndax Pharmaceuticals
  • Most Recent Events

    • 11 Nov 2017 According to a Syndax Pharmaceuticals media release, data from this trial were presented at the Society of Immunotherapy of Cancer (SITC) Annual Scientific Meeting
    • 11 Nov 2017 Results from non-small cell lung cancer (NSCLC) and melanoma cohorts of this trial published in the Syndax Pharmaceuticals Media Release
    • 07 Nov 2017 According to a Syndax Pharmaceuticals media release, enrollment in the first stage of the cohort of patients with microsatellite stable colorectal cancer (MSS-CRC) is complete, and a decision on whether to continue to the second stage is expected in the first quarter of 2018. Enrollment in the second stage of the PD-(L)1 refractory non-small cell lung cancer (NSCLC) cohort is complete, and Syndax expects to share updated data from this cohort in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top